LFG
NTLA icon

Larson Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Larson Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Buy
980
+688
+236% +$9.63K ﹤0.01% 2113
2026
Q1 		$3.74K Buy
292
+196
+204% +$2.5K ﹤0.01% 2736
2025
Q4 		$863 Sell
96
-34
-26% -$468 ﹤0.01% 2995
2025
Q3 		$2.25K Buy
130
+61
+88% +$751 ﹤0.01% 2657
2025
Q2 		$647 Buy
69
+39
+130% +$320 ﹤0.01% 2783
2025
Q1 		$213 Hold
30
– – ﹤0.01% 2785
2024
Q4 		$350 Sell
30
-32
-52% -$499 ﹤0.01% 2294
2024
Q3 		$1.27K Sell
62
-138
-69% -$3.18K ﹤0.01% 1940
2024
Q2 		$4.48K Buy
200
+170
+567% +$4.05K ﹤0.01% 1470
2024
Q1 		$825 Buy
30
+20
+200% +$556 ﹤0.01% 1485
2023
Q4 		$305 Buy
+10
New +$287 ﹤0.01% 1621

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Larson Financial Group's NTLA Position: Q2 2026 in Review

Larson Financial Group increased its Intellia Therapeutics (NTLA) stake by 236% in Q2 2026, buying an estimated $9.63K and bringing the position to 980 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

Larson Financial Group first reported a position in NTLA in Q4 2023 and has held it in 11 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Larson Financial Group held 980 shares of Intellia Therapeutics worth $16.6K as of Q2 2026.
  • Larson Financial Group bought 688 Intellia Therapeutics shares in Q2 2026, an estimated $9.63K.
  • Intellia Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2113 holding.
  • Larson Financial Group first reported a position in Intellia Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.